{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.2","upperLimit":"99.2","value":"93.1"},{"groupId":"OG001","lowerLimit":"89.9","upperLimit":"99.3","value":"96.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"Complete Hematologic Response (CHR) rate defined as the proportion of all treated participants who achieve a confirmed CHR while on-study. CHR is defined as including no more than 5% blasts in bone marrow and normal white blood cell count without blasts in peripheral blood. The percentage of treated participants in each arm with CHR is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 3"}],"paramType":"NUMBER","populationDescription":"Secondary efficacy endpoint pre-specified only for participants treated in Cohort 1 and Cohort 3","reportingStatus":"POSTED","timeFrame":"From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)","title":"Complete Hematologic Response (CHR) Rate in Cohorts 1 and 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}